Article Text

Download PDFPDF

2022-RA-1257-ESGO MILACC Study: Is the manipulation with LN containing undetected micrometastases the underlying cause of higher rate of local recurrences in the LACC trial?
  1. David Cibula1,
  2. Roni Nitecki2,
  3. Pavel Dundr3,
  4. Kristyna Nemejcova3,
  5. Reitan Ribeiro4,
  6. Mariano Tamura Vieira Gomes5,
  7. Ronaldo Luis Schmidt6,
  8. Lucio Bedoya7,
  9. David Isla Ortiz8,
  10. Rene Pareja9,
  11. Gabriel Jaime Rendón Pereira10,
  12. Aldo López Blanco11,
  13. David M Kushner12 and
  14. Pedro T Ramirez2
  1. 1Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
  2. 2Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, TX
  3. 3Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
  4. 4Department of Gynecologic Oncology, Erasto Gaertner Hospital, Curitiba, Brazil
  5. 5Department of Gynecologic Oncology, Albert Einstein Hospital, São Paulo, Brazil
  6. 6Department of Gynecologic Oncology, Barretos Cancer Hospital, Barretos, Brazil
  7. 7Department of Gynecologic Oncology, Hospital Misercordia, Cordoba, Argentina
  8. 8Department of Gynecologic Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico
  9. 9Department of Gynecologic Oncology, Instituto Nacional de Cancerología, Bogota, Colombia
  10. 10Department of Gynecologic Oncology, Instituto de Cancerologia Las Americas, Medellín, Colombia
  11. 11Department of Gynecologic Surgery, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
  12. 12Division of Gynecologic Oncology, University of Wisconsin-Madison, Madison, WI

Abstract

Introduction/Background Etiology of inferior oncologic outcomes in minimally invasive surgery (MIS) in early cervical cancer remains unknown. Manipulation of lymph nodes (LN) with low volume disease could explain the discrepancy in survival in the LACC trial. We reviewed all pelvic lymph nodes by pathological ultrastaging for the presence of micrometastases in node negative (H&E) patients who recurred in the LACC trial.

Methodology Eligible patients for MILACC study were patients previously randomized to the LACC trial, had negative LNs, and recurred to any site within the abdomen and pelvis. Patients without recurrence, without available LN tissue, or with distant recurrence were excluded. Paraffin tissue blocks and slides from all LN removed by lymphadenectomy during primary surgery were re-analyzed utilizing standard ultrastaging protocol (all analyzed by central pathological center), aiming at the detection of isolated tumor cells (clusters up to 0.2 mm in diameter or <200 cells) and micrometastases (>0.2 and ≤2 mm).

Results A total of 20 patients were included. Median age of the cohort was 43 (range: 30–68). Most patients had squamous cell carcinoma (70%), were randomized to MIS arm of LACC trial (85%), had stage 1B1 (95%), did not receive any adjuvant treatment post-operatively (75%), and had a single recurrence site (55%), most commonly at vaginal cuff and pelvis (both 45%). The median number of lymph nodes analyzed per patient was 19 (range: 4–32) for a total of 412 LN. A total of 621 series and 1242 slides were reviewed centrally by the ultrastaging protocol. No metastatic disease of any size was found in any LN.

Conclusion There was no LN small-volume metastases among patients with initial negative LN who recurred in the LACC trial. The hypothesis that manipulation of LN with occult low volume disease as an explanation for the worse oncologic outcomes is not supported by our study.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.